The 36-month beta value for FBIO is at 1.73. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for FBIO is 15.08M, and currently, shorts hold a 10.19% of that float. The average trading volume for FBIO on July 04, 2024 was 185.42K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
FBIO) stock’s latest price update
Fortress Biotech Inc (NASDAQ: FBIO)’s stock price has gone rise by 4.79 in comparison to its previous close of 1.67, however, the company has experienced a 2.94% increase in its stock price over the last five trading days. globenewswire.com reported 2024-07-02 that WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of an aggregate of 5,853,659 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.05 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, Checkpoint will issue and sell unregistered warrants to purchase up to 5,853,659 shares of common stock. The warrants will have an exercise price of $2.05 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrant and will expire five years following the issuance date.
FBIO’s Market Performance
FBIO’s stock has risen by 2.94% in the past week, with a monthly drop of -7.41% and a quarterly drop of -8.85%. The volatility ratio for the week is 6.34% while the volatility levels for the last 30 days are 6.43% for Fortress Biotech Inc The simple moving average for the past 20 days is -2.86% for FBIO’s stock, with a -23.48% simple moving average for the past 200 days.
Analysts’ Opinion of FBIO
Many brokerage firms have already submitted their reports for FBIO stocks, with ROTH MKM repeating the rating for FBIO by listing it as a “Buy.” The predicted price for FBIO in the upcoming period, according to ROTH MKM is $10 based on the research report published on March 15, 2024 of the current year 2024.
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see FBIO reach a price target of $6. The rating they have provided for FBIO stocks is “Buy” according to the report published on August 04th, 2022.
The Benchmark Company gave a rating of “Buy” to FBIO, setting the target price at $9 in the report published on October 02nd of the previous year.
FBIO Trading at -2.51% from the 50-Day Moving Average
After a stumble in the market that brought FBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.09% of loss for the given period.
Volatility was left at 6.43%, however, over the last 30 days, the volatility rate increased by 6.34%, as shares sank -4.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.57% upper at present.
During the last 5 trading sessions, FBIO rose by +3.53%, which changed the moving average for the period of 200-days by -66.48% in comparison to the 20-day moving average, which settled at $1.7975. In addition, Fortress Biotech Inc saw -41.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FBIO starting from ROSENWALD LINDSAY A MD, who purchase 20,000 shares at the price of $1.64 back on Jun 28 ’24. After this action, ROSENWALD LINDSAY A MD now owns 2,893,905 shares of Fortress Biotech Inc, valued at $32,724 using the latest closing price.
Klein Dov, the Director of Fortress Biotech Inc, sale 10,000 shares at $1.89 during a trade that took place back on May 20 ’24, which means that Klein Dov is holding 53,400 shares at $18,900 based on the most recent closing price.
Stock Fundamentals for FBIO
Current profitability levels for the company are sitting at:
- -1.41 for the present operating margin
- 0.68 for the gross margin
The net margin for Fortress Biotech Inc stands at -0.67. The total capital return value is set at -1.56. Equity return is now at value -179.27, with -25.46 for asset returns.
Based on Fortress Biotech Inc (FBIO), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at -1.55. The debt to equity ratio resting at 3.09. The interest coverage ratio of the stock is -20.04.
Currently, EBITDA for the company is -131.17 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 0.46. The receivables turnover for the company is 8.41for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.33.
Conclusion
In conclusion, Fortress Biotech Inc (FBIO) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
